A citation-based method for searching scientific literature

David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
Times Cited: 292



Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
Times Cited: 153




List of shared articles



Times cited

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
5

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Transpl Int 2021
5

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
7

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
0

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Rosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, Anne C Hesp, Peter J Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H van Raalte, Hiddo J L Heerspink. Diabetes Care 2021
12

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021
5

Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Georgia Anastasiou, Erifili Hatziagelaki, Evangelos Liberopoulos. J Cardiovasc Pharmacol 2021
2

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
Petter Bjornstad, Peter J Greasley, David C Wheeler, Glenn M Chertow, Anna Maria Langkilde, Hiddo J L Heerspink, DaniëL H Van Raalte. J Card Fail 2021
0


2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020
0

Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Francesco Spannella. Nutr Metab Cardiovasc Dis 2020
3

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Muhammad Shahzeb Khan, Muthiah Vaduganathan. Curr Diab Rep 2020
0


SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
24